Reducing inflammatory mediators during kidney perfusion
Research type
Research Study
Full title
A randomised pilot study to assess the safety and feasibility of adding a Cytosorb filter during kidney normothermic machine perfusion
IRAS ID
322728
Contact name
Stephen Kelleher
Contact email
Sponsor organisation
Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
Duration of Study in the UK
1 years, 4 months, 1 days
Research summary
The introduction of perfusion technologies in kidney transplantation has the potential to improve graft function and graft survival. It may also help to increase the number of kidney transplants by reducing damage caused during organ retrieval, cold preservation and after transplantation. We have developed a technique of perfusion called normothermic machine perfusion (NMP) which involves circulating an oxygenated blood-based solution through the kidney at a near normal body temperature to restore kidney function. Our previous work demonstrated that kidneys with high level of inflammation during NMP had significant graft dysfunction after transplantation. Early graft dysfunction increases the likelihood of complications, hospital stay, incidences of acute rejection and can reduce graft survival. The aim of this pilot study is to evaluate whether the removal of inflammatory mediators during NMP with the addition of a special filter (Cytocorb) to the system can reduce the inflammatory and immune response within the kidney after transplantation. This may improve early graft function. The results from the trial will inform the design of a large multicentre randomised clinical trial.
REC name
West Midlands - South Birmingham Research Ethics Committee
REC reference
23/WM/0141
Date of REC Opinion
27 Jul 2023
REC opinion
Further Information Favourable Opinion